top of page

Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC

Study of RYZ101 in Combination with SoC in Subjects with SSTR+ ES-SCLC


IDENTIFIER (ClinicalTrials.gov)NCT05595460


DRUG/TREATMENT: ALPHA PRRT with 225Ac-DOTATATE Actinium 225 radiolabeled somatostatin analog (SSA) for injection + Carboplatin + Etoposide + Atezolizumab


PHASE: 1b


STATUS: Recruiting


SPONSOR: RayzeBio, Inc.


DESCRIPTION:



Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the "Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC." Recorded: June 20, 2024


RayzeBio is sponsoring this phase 1b trial with ALPHA PRRT with 225Ac-DOTATATE for extensive stage small cell lung cancer (ES-SCLC). This trial studies the safety and dosimetry to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 (ALPHA PRRT with 225Ac-DOTATATE Actinium 225 radiolabeled somatostatin analog (SSA)  in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.


For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.


CONTACT:

RayzeBio Clinical Trials

EMAIL: clinicaltrials@rayzebio.com

PHONE: 619-657-0302


bottom of page